Akums Drugs & Pharma Quarterly Results
Akums Drugs & Pharma quarterly results. In Mar 2026, Akums Drugs & Pharma (AKUMS) reported revenue ₹1,193 Cr and net profit ₹81 Cr — revenue +10.4% YoY. Check AKUMS market cap trends to track the company's total market size over time.
AKUMS Quarterly Results — Revenue, Profit & EPS Highlights
Akums Drugs & Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review Akums Drugs & Pharma P/E valuation to evaluate earnings-based valuation against sector peers.
- Revenue of ₹1,193 Cr in Mar 2026 (-0.3% vs Jun 2026, +10.4% vs Mar 2025)
- Net Profit of ₹81 Cr in Mar 2026 (-19.8% vs Jun 2026, -46.0% vs Mar 2025)
- EBITDA of ₹185 Cr in Mar 2026 (-9.8% vs Jun 2026)
- Operating Margin of 13.0% in Mar 2026 (-2.0pp vs Jun 2026)
- Earnings Per Share of ₹5.53 in Mar 2026 (-15.3% vs Jun 2026)
Akums Drugs & Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
AKUMS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,193 | 1,197 | 1,050 | 1,081 | 1,051 | -0.3% | 10.4% |
| Net Profit (₹ Cr) | 81 | 101 | 43 | 150 | 65 | - | - |
| EBITDA (₹ Cr) | 185 | 205 | 127 | 120 | 156 | - | - |
| EPS (₹) | 5.53 | 6.53 | 2.66 | 9.64 | 4.15 | - | - |
| Operating Margin (%) | 13.0% | 15.0% | 9.0% | 9.0% | 13.0% | - | - |
AKUMS Share Price Trend — 1-Year Movement Across Quarterly Results
Akums Drugs & Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit AKUMS screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
AKUMS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Akums Drugs & Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹421,995.00 Cr | 1758.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 155.6 |
|
Divis Laboratories
Mar 2026 |
₹241,231.30 Cr | 9162.0 | 2,986 | 751 | -5.0% | - | 25.2% | 323.6 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4615.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 401.0 |
|
Laurus Labs
Mar 2026 |
₹111,790.60 Cr | 2002.5 | 1,823 | 282 | -10.5% | - | 15.5% | 387.3 |
|
Zydus Life Science
Mar 2026 |
₹111,111.95 Cr | 1135.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 89.7 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores